Veytics Intelligence
2026-10-21 · NASDAQ

Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech?

Key PointsAlnylam's stock has plunged more than 40% this year, but the company's financials look great.

Ler o briefing completo da Veytics

Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.